Prelude Therapeutics Inc (PRLD)
$5.79
Performance
- $5.74$6.00$5.79
0.86%
Downside
Day's Volatility :4.33%
Upside
3.5%
- $1.66$6.72$5.79
71.33%
Downside
52 Weeks Volatility :75.3%
Upside
13.84%
Returns
| Period | Prelude Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 47.17% | 6.5% | 0.0% |
6 Months | 67.32% | 7.1% | 0.0% |
1 Year | 45.39% | 9.8% | 0.0% |
3 Years | -82.03% | 14.2% | -20.2% |
Highlights
Market Capitalization | 320.2M |
Book Value | $3.84 |
Earnings Per Share (EPS) | -1.86 |
Wall Street Target Price | 4.75 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -38.59% |
Return On Equity TTM | -65.04% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -136.2M |
Diluted Eps TTM | -1.86 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.68 |
EPS Estimate Next Year | -1.42 |
EPS Estimate Current Quarter | -0.48 |
EPS Estimate Next Quarter | -0.49 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Downside of 17.96%
Technicals Summary
Sell
Neutral
Buy
Prelude Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Prelude Therapeutics Inc | 61.89% | 67.32% | 45.39% | -82.03% | -77.14% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Prelude Therapeutics Inc | NA | NA | NA | -1.68 | -0.65 | -0.39 | NA | 3.84 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Prelude Therapeutics Inc | Sell | $320.2M | -77.14% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Prelude Therapeutics Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 16.2%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 268.5%
Institutional Holdings
Orbimed Advisors, LLC
19.86%Baker Bros Advisors LP
18.43%Deerfield Management Co
7.52%Boxer Capital LLC
4.68%BlackRock Inc
2.00%Vanguard Group Inc
1.85%
Company Information
prelude therapeutics incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. it is developing prt543 that is in phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and prt811, which is in phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. the company is also developing prt1419, a potent and selective inhibitor of the anti-apoptotic protein; prt2527, a potent inhibitor of cdk9 that exhibits high kinome selectivity; prt-sca2 for multiple genomically selected cancers; and prt-k4 for solid tumors. prelude therapeutics incorporated was founded in 2016 and is based in wilmington, delaware.
Organization | Prelude Therapeutics Inc |
Employees | 128 |
CEO | Dr. Krishna Vaddi D.V.M., Ph.D. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$5.79
-3.34%
Keyarch Acquisition Corp
$5.79
-3.34%
Connexa Sports Technologies Inc
$5.79
-3.34%
Us Value Etf
$5.79
-3.34%
First Wave Biopharma Inc
$5.79
-3.34%
Global X Msci Next Emerging
$5.79
-3.34%
Fat Projects Acquisition Corp
$5.79
-3.34%
Capital Link Global Fintech
$5.79
-3.34%
Applied Uv Inc
$5.79
-3.34%